HUTCHMED (China) Limited announced that Dr. Weiguo Su will take a leave of absence due to health reasons, appointing Mr. Johnny Cheng as Acting CEO. The Board expresses support for Dr. Su and confidence in Mr. Cheng’s leadership. HUTCHMED focuses on cancer and immunological disease therapies, with three medicines marketed in China and globally. Mr. Cheng, previously CFO, has been an Executive Director since 2011. He has no relationships with other directors or shareholders and holds approximately 0.34% of company shares. Emoluments for Mr. Cheng are determined by company performance and market conditions. For further information, visit www.hutch-med.com.

Read more at GlobeNewswire: HUTCHMED Announces Appointment of Acting Chief Executive